Tags

Type your tag names separated by a space and hit enter

Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index.
Breast Cancer Res. 2013; 15(5):R98.BC

Abstract

INTRODUCTION

Recurrence risk in breast cancer varies throughout the follow-up time. We examined if these changes are related to the level of expression of the proliferation pathway and intrinsic subtypes.

METHODS

Expression of estrogen and progesterone receptor, Ki-67, human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR) and cytokeratin 5/6 (CK 5/6) was performed on tissue-microarrays constructed from a large and uniformly managed series of early breast cancer patients (N = 1,249). Subtype definitions by four biomarkers were as follows: luminal A (ER + and/or PR+, HER2−, Ki-67 <14), luminal B (ER + and/or PR+, HER2−, Ki-67 ≥14), HER2-enriched (any ER, any PR, HER2+, any Ki-67), triple-negative (ER−, PR−, HER2−, any Ki-67). Subtype definitions by six biomarkers were as follows: luminal A (ER + and/or PR+, HER2−, Ki-67 <14, any CK 5/6, any EGFR), luminal B (ER + and/or PR+, HER2−, Ki-67 ≥14, any CK 5/6, any EGFR), HER2-enriched (ER−, PR−, HER2+, any Ki-67, any CK 5/6, any EGFR), Luminal-HER2 (ER + and/or PR+, HER2+, any Ki-67, any CK 5/6, any EGFR), Basal-like (ER−, PR−, HER2−, any Ki-67, CK5/6+ and/or EGFR+), triple-negative nonbasal (ER−, PR−, HER2−, any Ki-67, CK 5/6−, EGFR−). Each four- or six-marker defined intrinsic subtype was divided in two groups, with Ki-67 <14% or with Ki-67 ≥14%. Recurrence hazard rate function was determined for each intrinsic subtype as a whole and according to Ki-67 value.

RESULTS

Luminal A displayed a slow risk increase, reaching its maximum after three years and then remained steady. Luminal B presented most of its relapses during the first five years. HER2-enriched tumors show a peak of recurrence nearly twenty months post-surgery, with a greater risk in Ki-67 ≥14%. However a second peak occurred at 72 months but the risk magnitude was greater in Ki-67 <14%. Triple negative tumors with low proliferation rate display a smooth risk curve, but with Ki-67 ≥14% show sharp peak at nearly 18 months.

CONCLUSIONS

Each intrinsic subtype has a particular pattern of relapses over time which change depending on the level of activation of the proliferation pathway assessed by Ki-67. These findings could have clinical implications both on adjuvant treatment trial design and on the recommendations concerning the surveillance of patients.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24148581

Citation

Ribelles, Nuria, et al. "Pattern of Recurrence of Early Breast Cancer Is Different According to Intrinsic Subtype and Proliferation Index." Breast Cancer Research : BCR, vol. 15, no. 5, 2013, pp. R98.
Ribelles N, Perez-Villa L, Jerez JM, et al. Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. Breast Cancer Res. 2013;15(5):R98.
Ribelles, N., Perez-Villa, L., Jerez, J. M., Pajares, B., Vicioso, L., Jimenez, B., de Luque, V., Franco, L., Gallego, E., Marquez, A., Alvarez, M., Sanchez-Muñoz, A., Perez-Rivas, L., & Alba, E. (2013). Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. Breast Cancer Research : BCR, 15(5), R98.
Ribelles N, et al. Pattern of Recurrence of Early Breast Cancer Is Different According to Intrinsic Subtype and Proliferation Index. Breast Cancer Res. 2013;15(5):R98. PubMed PMID: 24148581.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. AU - Ribelles,Nuria, AU - Perez-Villa,Lidia, AU - Jerez,Jose Manuel, AU - Pajares,Bella, AU - Vicioso,Luis, AU - Jimenez,Begoña, AU - de Luque,Vanessa, AU - Franco,Leonardo, AU - Gallego,Elena, AU - Marquez,Antonia, AU - Alvarez,Martina, AU - Sanchez-Muñoz,Alfonso, AU - Perez-Rivas,Luis, AU - Alba,Emilio, PY - 2013/04/30/received PY - 2013/10/07/accepted PY - 2013/10/24/entrez PY - 2013/10/24/pubmed PY - 2014/9/12/medline SP - R98 EP - R98 JF - Breast cancer research : BCR JO - Breast Cancer Res VL - 15 IS - 5 N2 - INTRODUCTION: Recurrence risk in breast cancer varies throughout the follow-up time. We examined if these changes are related to the level of expression of the proliferation pathway and intrinsic subtypes. METHODS: Expression of estrogen and progesterone receptor, Ki-67, human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR) and cytokeratin 5/6 (CK 5/6) was performed on tissue-microarrays constructed from a large and uniformly managed series of early breast cancer patients (N = 1,249). Subtype definitions by four biomarkers were as follows: luminal A (ER + and/or PR+, HER2−, Ki-67 <14), luminal B (ER + and/or PR+, HER2−, Ki-67 ≥14), HER2-enriched (any ER, any PR, HER2+, any Ki-67), triple-negative (ER−, PR−, HER2−, any Ki-67). Subtype definitions by six biomarkers were as follows: luminal A (ER + and/or PR+, HER2−, Ki-67 <14, any CK 5/6, any EGFR), luminal B (ER + and/or PR+, HER2−, Ki-67 ≥14, any CK 5/6, any EGFR), HER2-enriched (ER−, PR−, HER2+, any Ki-67, any CK 5/6, any EGFR), Luminal-HER2 (ER + and/or PR+, HER2+, any Ki-67, any CK 5/6, any EGFR), Basal-like (ER−, PR−, HER2−, any Ki-67, CK5/6+ and/or EGFR+), triple-negative nonbasal (ER−, PR−, HER2−, any Ki-67, CK 5/6−, EGFR−). Each four- or six-marker defined intrinsic subtype was divided in two groups, with Ki-67 <14% or with Ki-67 ≥14%. Recurrence hazard rate function was determined for each intrinsic subtype as a whole and according to Ki-67 value. RESULTS: Luminal A displayed a slow risk increase, reaching its maximum after three years and then remained steady. Luminal B presented most of its relapses during the first five years. HER2-enriched tumors show a peak of recurrence nearly twenty months post-surgery, with a greater risk in Ki-67 ≥14%. However a second peak occurred at 72 months but the risk magnitude was greater in Ki-67 <14%. Triple negative tumors with low proliferation rate display a smooth risk curve, but with Ki-67 ≥14% show sharp peak at nearly 18 months. CONCLUSIONS: Each intrinsic subtype has a particular pattern of relapses over time which change depending on the level of activation of the proliferation pathway assessed by Ki-67. These findings could have clinical implications both on adjuvant treatment trial design and on the recommendations concerning the surveillance of patients. SN - 1465-542X UR - https://www.unboundmedicine.com/medline/citation/24148581/Pattern_of_recurrence_of_early_breast_cancer_is_different_according_to_intrinsic_subtype_and_proliferation_index_ L2 - https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3559 DB - PRIME DP - Unbound Medicine ER -